Sanofi Shares Bounce to €76.53 After Phase 2 Success of ElevAATe
Sanofi shares rise by 1.77% to €76.53 mid-session, as the CAC 40 gains 0.73%. The company is among the top performers on the CAC 40 following the positive results from the phase 2 ElevAATe study on efdoralprin alfa. The stock is now back to its 20-day moving average after hitting a low of €71.73 on May 12.
The rebound of efdoralprin alfa breathes new life into the stock after a six-year low
Today's rebound follows the phase 2 data unveiled on May 19 regarding efdoralprin alfa, an experimental treatment for patients with emphysema linked to alpha-1 antitrypsin deficiency. The ElevAATe study met its primary endpoint, as detailed in the clinical results publication. The data were presented at the annual American Thoracic Society conference in Orlando. The Sanofi stock is recovering after a challenging period: on May 12, the share price had fallen to €71.73, a six-year low that erased the Covid crash trough of 2020 (€72.74). The decline then reached 3.13% over three months and 17.05% over a year. Today's session partially offsets this lag, though it does not erase the annual decline. Sanofi remains 17% below its price from a year ago. The schedule remains busy: the next financial publication, the second quarter 2026 results, is expected on July 30.
The stock approaches its MM20 but remains 6.4% below its 200-day average
In terms of indicators, the price of €76.53 is now close to the 20-day moving average (€76.45), a threshold crossed thanks to the rebound. The 200-day average, at €81.79, remains about 6.4% above the current price, reflecting the underlying bearish trend. The RSI at 44 remains in the neutral zone. Regarding valuation, the consensus of nineteen analysts (updated May 16) stands at about 9 times the earnings for the current fiscal year, compared to an average of 22.4 times for the Health Care sector. The EPS growth expected by analysts for this year is 5.8%.
